Recently, CT Tianqing Pharmaceutical's self-developed Class 1 new drug TQB2102 for injection has obtained the implied license of clinical trials and is intended to be used for the treatment of advanced malignant tumors
.
According to the data, TQB2102 for injection is an antibody conjugate drug (ADC)
independently developed by Chia Tai Tianqing Pharmaceutical that targets two non-overlapping epitopes of HER2, ECD2 and ECD4.
Compared with monoclonal antibody and monoclonal antibody ADC, HER2 bispecific antibody ADC has stronger binding, internalization efficiency and killing effect on tumor cells, and has advantages
for tumors with low expression of HER2.
It is understood that at present, a number of domestic and foreign companies have laid out targeted HER2 bispecific antibody ADC drugs, and the rapid research has entered the clinical stage
.
There are no products targeting HER2 dual antibody ADC on the market at home and abroad, and the industry expects that if TQB2102 monoclonal antibody can be successfully launched, it will show significant efficacy in the field of malignant tumors and usher in considerable benefits
.
It is worth mentioning that anti-tumor drugs are the key R&D areas of CP Tianqing Pharmaceutical, and since the beginning of this year, the company has submitted 7 anti-tumor class 1 new drugs for clinical applications, and all of them have been approved for clinical trials; Two anti-tumor class 1 new drugs were submitted for marketing applications, namely TQ-B3101 capsules (ROS1/ALK/c-Met inhibitors) and TQ-B3139 capsules (ALK inhibitors).
Industry analysts believe that Chia Tai Tianqing Pharmaceutical's fierce attack on anti-tumor drugs is mainly based on the broad
market space in this field.
It is reported that in recent years, with the rise in clinical drug demand and the acceleration of the approval and volume of innovative drugs, anti-tumor and immunomodulatory agents have become the first drugs in the hospital market
.
According to data, in 2021, the sales scale of terminal anti-tumor and immunomodulatory agents in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) exceeded 170 billion yuan, a year-on-year increase of 10.
93%.
In fact, in addition to Chia Tai Tianqing Pharmaceutical, anti-tumor drugs have always been a hot target for domestic and foreign pharmaceutical companies
.
According to combing, from January 1, 2022 to December 31, 2022, the State Food and Drug Administration approved a total of 51 new drugs for marketing, although there is a large gap compared with the batch of 83 models in 2021, but it is basically the same
as 53 models in 2018, 54 models in 2019 and 49 models in 2020.
From the perspective of treatment direction, the 51 new drugs approved are still mostly anti-tumor products, and statistics show that a total of 22 anti-tumor drugs have been approved this year, covering liver cancer, lung cancer, cholangiocarcinoma, breast cancer, prostate cancer, cervical cancer, lymphoma and other
cancers.
In China, cancer treatment is also one of the key areas of China's medical and health development, and many domestic pharmaceutical companies are accelerating the research and development and application
of new anti-tumor drugs.
In this context, the results are also beginning to appear
.
For example, on December 2, Henlius announced on the Hong Kong Stock Exchange that the first patient dosing
in a Phase 1 clinical study of HLX60 (recombinant anti-GARP humanized monoclonal antibody injection) for the treatment of solid tumors and lymphomas in China (excluding Hong Kong, Macao and Taiwan).
HLX60 is an innovative anti-GARP monoclonal antibody independently developed by the company, which is planned to be used in the treatment
of solid tumors and lymphomas.
On November 24, Huahai Pharmaceutical announced that its subsidiary Shanghai Huaaotai's independent research and development of HB0045 injection for the treatment of advanced solid tumors has been approved by the US Food and Drug Administration (FDA).
The industry believes that from the new progress in the research and development of a large number of domestic anti-tumor new drugs, it can be seen that the innovative research and development of anti-tumor innovative drugs in China is advancing
rapidly.
In the future, more and more domestic anti-tumor new drugs will continue to emerge, providing more new treatment options
for the majority of patients.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
